☆ 4.5 Article

Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Clinical Neurology

Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis

Giovanna Fico et al.

Summary: This systematic review and meta-analysis investigates the repurposing of psychotropic drugs in the treatment of COVID-19. The study finds that antidepressants do not significantly affect the risk and mortality of COVID-19, while fluvoxamine may have potential in reducing mortality risk. Antipsychotics may increase the risk of severe COVID-19 and mortality, but their use in psychiatric patients should be evaluated on a case-by-case basis.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

Add to Collection

Article Psychiatry

Heightened COVID-19 Mortality in People With Severe Mental Illness Persists After Vaccination: A Cohort Study of Greater Manchester Residents

Lamiece Hassan et al.

Summary: Previous studies have shown that people with severe mental illness (SMI) are at higher risk of COVID-19 mortality. This study investigated COVID-19 mortality among people with schizophrenia and other SMIs before, during, and after the UK vaccine roll-out. The results showed that people with SMI, particularly those with schizophrenia and bipolar disorder (BD), were at greater risk of COVID-19 mortality compared to matched controls. Disparities in COVID-19 mortality for people with SMI still exist despite vaccination efforts.

SCHIZOPHRENIA BULLETIN (2023)

Add to Collection

Article Pharmacology & Pharmacy

Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls

Martina Calusic et al.

Summary: Fluvoxamine, as an early treatment option, has shown promise in preventing COVID-19 progression in three trials. This study evaluated the safety and efficacy of fluvoxamine in COVID-19 patients when administered later in the disease course. The results suggest that fluvoxamine treatment in addition to standard therapy may have a positive impact on patient survival, but further studies are needed to confirm these findings.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Mechanisms of action of fluvoxamine for COVID-19: a historical review

Yaeko Hashimoto et al.

Summary: The ongoing COVID-19 pandemic has sparked interest in drug repurposing, particularly in the use of antidepressants. Clinical data suggest that early-stage COVID-19 patients who take antidepressants may have a lower risk of intubation or death. Fluvoxamine, among antidepressants, is the most attractive drug for mild to moderate COVID-19 cases. Additionally, there may be a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders in offspring, such as autism spectrum disorder and schizophrenia.

MOLECULAR PSYCHIATRY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The acid sphingomyelinase/ceramide system in COVID-19

Johannes Kornhuber et al.

Summary: ASM cleaves sphingomyelin into ceramide, which SARS-CoV-2 uses for cell entry. Lowering ceramide levels or blocking its action can protect cells against infection. Several clinically approved drugs that inhibit ASM have shown beneficial effects against COVID-19.

MOLECULAR PSYCHIATRY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

Gilmar Reis et al.

Summary: Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to a tertiary hospital. The trial showed a higher probability of superiority (99.8%) surpassing the prespecified threshold of 97.6%.

LANCET GLOBAL HEALTH (2022)

Add to Collection

Article Medicine, General & Internal

Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis

Steven H. Rauchman et al.

Summary: Short-term use of SSRI antidepressants can reduce the severity of symptoms in COVID-positive patients. This study highlights the usefulness of large clinical databases in identifying commonly used drugs that may be helpful in treating COVID-19.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Immunology

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection

Ariel Israel et al.

Summary: This study demonstrates that individuals who received the Pfizer-BioNTech mRNA vaccine have higher initial levels of antibodies compared to patients who had been infected with the SARS-CoV-2 virus, but experience a much faster exponential decrease in antibody levels.

VACCINES (2022)

Add to Collection

Editorial Material Medicine, General & Internal

COVID-19 in 2022-The Beginning of the End or the End of the Beginning?

Carlos Del Rio et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Medicine, General & Internal

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study

Cristina Menni et al.

Summary: This study investigated the differences in symptom prevalence, risk of hospital admission, and symptom duration between omicron and delta variants of the SARS-CoV-2 virus. The study found that loss of smell was less common in omicron infections, sore throat was more common, and the rate of hospital admission was lower.

LANCET (2022)

Add to Collection

Article Psychiatry

Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study

Nicolas Hoertel et al.

Summary: The study found that the use of FIASMA psychotropic medications may reduce the risk of intubation or death in COVID-19 patients. Especially, patients taking FIASMA antidepressants have a lower risk compared to those taking non-FIASMA antidepressants. These findings are important for further evaluating the effectiveness of FIASMA medications against COVID-19.

TRANSLATIONAL PSYCHIATRY (2022)

Add to Collection

Article Multidisciplinary Sciences

Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies

Omnia Kutkat et al.

Summary: This study evaluated the efficacy of eight commonly used FDA-approved antidepressants in inhibiting the novel coronavirus and found that some of these drugs showed potential antiviral activity. These findings suggest the need for further research on the potential effects of these drugs in treating COVID-19 in patients with depression.

SCIENTIFIC REPORTS (2022)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Decision making in global health: is everyone on board?

[Anonymous]

LANCET GLOBAL HEALTH (2022)

Add to Collection

Article Health Care Sciences & Services

COVID-19 mortality burden and comorbidity patterns among decedents with and without intellectual and developmental disability in the US

Scott D. Landes et al.

Summary: This study reveals that individuals with intellectual and developmental disability (IDD) faced a higher risk of mortality during the first year of the COVID-19 pandemic. COVID-19 was the leading cause of death among decedents with IDD, and the proportion of deaths from COVID-19 was higher for decedents with IDD compared to those without IDD. Comorbidities resulting from COVID-19 were similar between the two groups, but there were some differences in reported pre-existing conditions, notably higher rates of hypothyroidism and seizures among decedents with IDD.

DISABILITY AND HEALTH JOURNAL (2022)

Add to Collection

Article Psychiatry

Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2

Bradley A. Fritz et al.

Summary: Antidepressant exposure is associated with a reduced incidence of emergency department visitation or hospital admission among SARS-CoV-2 positive patients, in a dose-dependent manner. These data support the FIASMA model of antidepressants' effects against COVID-19.

TRANSLATIONAL PSYCHIATRY (2022)

Add to Collection

Review Public, Environmental & Occupational Health

Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis

Li-Chin Lu et al.

Summary: This meta-analysis investigated the use of fluvoxamine for the treatment of nonhospitalized patients with COVID-19. The results showed that fluvoxamine can be safely used in these patients and reduce the hospitalization rate or emergency department visits.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)

Add to Collection

Article Medicine, General & Internal

Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19

Nicolas Hoertel et al.

Summary: To reduce mortality and morbidity related to COVID-19, there is an urgent need for widely available oral COVID-19 treatments. Certain antidepressants may be beneficial against COVID-19 and reduce mortality rates among hospitalized patients.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

The Lancet Commission on lessons for the future from the COVID-19 pandemic

Jeffrey D. Sachs et al.

LANCET (2022)

Add to Collection

Article Psychiatry

Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study

N. Hoertel et al.

Summary: This study found a significant association between the use of benzodiazepine receptor agonists (BZRAs) and increased mortality in patients hospitalized for COVID-19, with a dose-dependent relationship. Diazepam may be associated with reduced mortality compared to other BZRA treatments.

EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2022)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

New waves, new variants, old inequity: a continuing COVID-19 crisis

Senjuti Saha et al.

BMJ GLOBAL HEALTH (2021)

Add to Collection

Review Clinical Neurology

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor

Kenji Hashimoto

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has spurred the search for effective treatments. Research has shown the significance of the sigma-1 receptor in SARS-CoV-2 replication, suggesting the repurposing of CNS drugs targeting this receptor for treatment. Promising results from trials with fluvoxamine have highlighted the potential for antidepressants in preventing clinical deterioration in COVID-19 patients.

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2021)

Add to Collection

Article Infectious Diseases

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021

Lin T. Brandal et al.

Summary: In the Omicron SARS-CoV-2 outbreak in Oslo, Norway, most infected individuals were aged 30-50, 96% were vaccinated, with an attack rate of 74%, but none required hospitalization.

EUROSURVEILLANCE (2021)

Add to Collection

News Item Multidisciplinary Sciences

COULD NEW COVID VARIANTS UNDERMINE VACCINES? LABS SCRAMBLE TO FIND OUT

Ewen Callaway

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Mohd Imran et al.

Summary: Molnupiravir, developed initially for influenza treatment, has shown promising activity against various viruses, including SARS-CoV-2. With good safety profile and oral bioavailability, it is currently in development for treating COVID-19 and expected to be available in an oral dosage form in 2022. Patent data suggests potential combinations with other drugs to enhance efficacy.

MOLECULES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

CDC Interim Recommendations for Fully Vaccinated People An Important First Step

Athalia Christie et al.

Summary: The CDC recommends that fully vaccinated individuals can resume low-risk gatherings but should maintain public health measures in activities involving unvaccinated people.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study

Nicolas Hoertel et al.

Summary: This study suggests that the use of antidepressants in patients hospitalized for COVID-19 may be associated with a lower risk of death or intubation. Antidepressants such as fluoxetine, paroxetine, escitalopram, venlafaxine, and mirtazapine showed significant associations with reduced risk. Further research in the form of double-blind controlled randomized clinical trials is recommended.

MOLECULAR PSYCHIATRY (2021)

Add to Collection

News Item Multidisciplinary Sciences

HOW TO REDESIGN COVID VACCINES SO THEY PROTECT AGAINST VARIANTS

Ewen Callaway et al.

NATURE (2021)

Add to Collection

Article Immunology

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

David Seftel et al.

Summary: In this study, 65 individuals opted to receive fluvoxamine for COVID-19 treatment, with a 0% hospitalization rate and 0% residual symptoms. In comparison, 48 individuals who chose observation alone had a hospitalization rate of 12.5% and residual symptoms in 60% of cases. This suggests that fluvoxamine may help alleviate the severity and duration of COVID-19.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue

Melissa Zimniak et al.

Summary: Research has found that Fluoxetine can effectively inhibit SARS-CoV-2 infection and show activity in human lung tissue. Both stereoisomers of Fluoxetine exhibit similar activity against the virus, with the R-form possibly being specifically used for SARS-CoV-2 treatment.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19

Vikas P. Sukhatme et al.

Summary: Fluvoxamine, a well-tolerated and widely available selective serotonin reuptake inhibitor, has shown potential in preventing clinical deterioration of COVID-19 patients in a small study. It functions through various mechanisms such as antiviral effects, anti-inflammatory properties, and regulation of coagulopathy.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Clinical Neurology

Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Yaser Pashaei

Summary: COVID-19 is considered the most challenging pandemic in the 21st century with no specific therapeutic strategy. Research suggests that fluoxetine may serve as an adjuvant therapeutic agent for COVID-19, potentially reducing inflammatory responses and neurological complications.

JOURNAL OF CLINICAL NEUROSCIENCE (2021)

Add to Collection

Letter Medicine, General & Internal

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Madhumita Shrotri et al.

LANCET (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms

Nicolas Hoertel et al.

MOLECULAR PSYCHIATRY (2021)

Add to Collection

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

Add to Collection

News Item Critical Care Medicine

Repurposing drugs for treatment of COVID-19

Priya Venkatesan

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Psychiatry

Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?

Robyn P. Thom et al.

Summary: Long-term use of SSRIs can prevent relapse but also increase the risk of tachyphylaxis and discontinuation syndrome. Prescribers should consider the patient's condition, safety, and tolerability of the medication when deciding whether to continue using SSRIs and should reassess periodically.

JOURNAL OF PSYCHIATRIC PRACTICE (2021)

Add to Collection

Article Medicine, General & Internal

Will vaccination refusal prolong the war on SARS-CoV-2?

Robert Marcec et al.

Summary: A survey conducted in 2020 across 26 European countries revealed that only 58% of respondents were willing to get a SARS-CoV-2 vaccine, 16% were neutral, and 26% were not planning to vaccinate. This low vaccination response could hinder the achievement of herd immunity against SARS-CoV-2. Educational public health activities on vaccination are crucial to improve attitudes and combat the prolongation of the COVID-19 pandemic before a vaccine becomes widely available.

POSTGRADUATE MEDICAL JOURNAL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Dual targeting of 3CL(pro) and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19

Sajjan Rajpoot et al.

Summary: The paper proposes repurposing FDA-approved drugs for preventive and therapeutic use against SARS-CoV-2, focusing on designing a dual-inhibitor for the cysteine proteases of the virus. Through virtual screening, nine dual-targeting inhibitors for 3CL(pro) and PLpro were selected, which block key catalytic sites of these enzymes. Repurposing known drugs can expedite the search for effective anti-coronaviral drugs.

CURRENT RESEARCH IN STRUCTURAL BIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Francisco J. de Abajo et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial

Eric J. Lenze et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Neurosciences

The Impact of Dementia on the Clinical Outcome of COVID-19: A Systematic Review and Meta-Analysis

Nanyang Liu et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

Add to Collection

Article Immunology

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2

Xia Xiao et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Immunology

Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis

Lina Wang et al.

BRAIN BEHAVIOR AND IMMUNITY (2019)

Add to Collection

Review Psychiatry

Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium

Gara Arteaga-Henriquez et al.

FRONTIERS IN PSYCHIATRY (2019)

Add to Collection

Review Immunology

The complexity and cost of vaccine manufacturing - An overview

Stanley Plotkin et al.

VACCINE (2017)

Add to Collection

Article Neurosciences

The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells

Jeffrey M. Greeson et al.

BIOLOGICAL PSYCHIATRY (2016)

Add to Collection

Editorial Material Medicine, General & Internal

Real-World Evidence - What Is It and What Can It Tell Us?

Rachel E. Sherman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Behavioral Sciences

Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration

Chao Dong et al.

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2016)

Add to Collection

Review Biotechnology & Applied Microbiology

Medication Adherence Measures: An Overview

Wai Yin Lam et al.

BIOMED RESEARCH INTERNATIONAL (2015)

Add to Collection

Article Public, Environmental & Occupational Health

Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications

Carola A. Huber et al.

BMC PUBLIC HEALTH (2013)

Add to Collection

Article Behavioral Sciences

Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration

Yuta Ohgi et al.

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2013)

Add to Collection

Article Immunology

A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia

Ross J. Tynan et al.

BRAIN BEHAVIOR AND IMMUNITY (2012)

Add to Collection

Article Medicine, General & Internal

New Decade of Vaccines 3 Vaccine production, distribution, access, and uptake

Jon Smith et al.

LANCET (2011)

Add to Collection

Article Rheumatology

Fluoxetine and Citalopram Exhibit Potent Antiinflammatory Activity in Human and Murine Models of Rheumatoid Arthritis and Inhibit Toll-like Receptors

Sandra Sacre et al.

ARTHRITIS AND RHEUMATISM (2010)

Add to Collection

Article Psychiatry

Selective Serotonin Reuptake Inhibitor Suppression of HIV Infectivity and Replication

Tami Benton et al.

PSYCHOSOMATIC MEDICINE (2010)

Add to Collection

Article Mathematical & Computational Biology

Why Match? Investigating Matched Case-Control Study Designs with Causal Effect Estimation

Sherri Rose et al.

INTERNATIONAL JOURNAL OF BIOSTATISTICS (2009)

Add to Collection

Article Neurosciences

The role of cohort studies in drug development: Clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system

Scott L. Letendre et al.

JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.